Institutional Sign In

Go

GlaxoSmithKline Czech Republic - Net Debt/Equity

GlaxoSmithKline CR`s Net Debt/Equity reached -13.8 % in 2017. This is 40.1 % less than in the previous year.

$1.99

Buy Net Debt/Equity data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...             0 0 -0.133 18.6 38.7    
Bayer Czech Republic % ... ... ...                 -10.9 -3.80 6.64 8.88 60.8    
GlaxoSmithKline Czech Republic % ... ... ...                 9.97 17.5 23.8 -0.015 -38.5    
Merck Czech Republic % ... ...                   55.8 40.2 43.6 5.40 -0.588    
Novartis Czech Republic %                       83.3 16.7 -1.34 22.0 -0.390    
Pfizer Czech Republic % ... ...                   66.1 -8.43 -1.56 -16.8 -0.350    
Roche Czech Republic % ... ... ...                 -0.035 13.7 23.0 47.7 55.7   ...
Sanofi-Aventis Czech Republic % ... ... ... ...               221 232 137 73.7 57.8    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... -89.2 -89.7 -59.8 -26.5    
Walmark % ... ... ...                 13.3 195 86.8 73.0 -1,526